Status:

TERMINATED

Treating Multiple Sclerosis With Sirolimus, an Immune System Suppressor

Lead Sponsor:

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborating Sponsors:

Autoimmunity Centers of Excellence

Conditions:

Multiple Sclerosis (MS) - Relapsing-remitting

Eligibility:

All Genders

18-58 years

Phase:

PHASE1

PHASE2

Brief Summary

The purpose of this study is to determine the safety and tolerability of the drug sirolimus in patients with multiple sclerosis (MS) who have failed other treatments.

Detailed Description

MS is a chronic autoimmune disease of the central nervous system in which myelin, the protein sheath that protects nerve cells, is degraded by T cells and macrophages, leading to an eventual loss of n...

Eligibility Criteria

Inclusion

  • Relapsing-remitting MS
  • Evidence of demyelination on magnetic resonance imaging (MRI) scan
  • Expanded Disability Status Scale (EDSS) score between 0 and 6
  • Nonresponsive to beta-interferon or Glatiramer acetate therapy
  • Discontinuation of beta-interferon or Glatiramer acetate therapy within 1 month prior to study entry
  • Willing to use acceptable methods of contraception

Exclusion

  • Primary progressive MS
  • Prior treatment with immunosuppressants
  • Steroid therapy within 1 month prior to study entry
  • Evidence of active infection or cancer
  • Heart or hematologic dysfunction
  • High levels of lipids in the blood
  • Use of lipid-lowering agents
  • History of cirrhosis or liver disease requiring treatment
  • History of hepatitis B or C
  • Active cytomegalovirus infection
  • Kidney disease requiring treatment
  • Active lung disease
  • Diabetes
  • Hyperthyroidism
  • HIV infection
  • Tuberculosis
  • History of alcohol or drug abuse within 6 months prior to study entry
  • Claustrophobia or inability to undergo MRI
  • Pregnancy or breast-feeding

Key Trial Info

Start Date :

May 1 2003

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2005

Estimated Enrollment :

14 Patients enrolled

Trial Details

Trial ID

NCT00095329

Start Date

May 1 2003

End Date

March 1 2005

Last Update

September 22 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Center for Neurological Diseases, Brigham and Women's Hospital, Harvard Medical School

Boston, Massachusetts, United States, 02115